LONDON, May 20 (Reuters) - Roche's breast cancer
drug Perjeta, or pertuzumab, has been turned down for use on
Britain's state health service, making it the latest in a number
of pricey new cancer treatments deemed not to offer value for
money.
Read more
No comments:
Post a Comment